PROF CHEN

It is important to highlight that Shawn is renowned not only for his basic medical research, but also for clinical translation of his work. For example, 177Lu-LNC1004 developed by Prof. Chen is a new therapeutic radiopharmaceutical that has received approval from US FDA, Singapore HSA and China NMPA, to treat patients with advanced solid tumors, especially those who have metastasis to remote organs/tissues. The clinical data obtained so far suggest substantially better progression survival rate (PFS) and overall response rate (ORR) than the current standard of care. Prof. Chen also came up with a platform technology to further develop various types of radiopharmaceuticals as precision medicine to treat cancer, cardiovascular disease, and autoimmune diseases. So far, Prof. Chen's team has secured over 10 INDs in total for disease diagnosis and therapy, which will eventually shape the future of how cancer patients will be managed and effectively treated. A start-up company (Yantai LNC)..

Primary location: Singapore